MTGR1 Polyclonal Antibody, Biotin Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-8304R-Biotin |
| Product Name | MTGR1 Polyclonal Antibody, Biotin Conjugated |
| Applications |
WB
ELISA
IHC-P
IHC-F
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Pig, Horse, Chicken |
| Specifications | |
| Conjugation | Biotin |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human MTGR1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C for 12 months. |
| Target | |
| Gene ID | 9139 |
| Subcellular location | Nucleus |
| Synonyms | AML1 MTG8; CBFA2T2; Core binding factor runt domain alpha subunit 2 translocated to 2; EHT; ETO homolog on chromosome 20; ETO homologous on chromosome 20; MTG 8 like protein; MTG 8 related protein 1; MTG8 like protein; MTG8 related protein 1; MTG8-like protein; MTG8-related protein 1; MTG8R_HUMAN; MTGR 1; Myeloid translocation gene related protein 1; Myeloid translocation related protein 1; Myeloid translocation-related protein 1; p85; Protein CBFA2T2; ZMYND 3; ZMYND3. |
| Background | May function as a complex with the chimeric protein RUNX1/AML1-CBFA2T1/MTG8 which is produced in acute myeloid leukemia with the chromosomal translocation t(8;21). May thus be involved in the repression of AML1-dependent transcription and the induction of G-CSF/CSF3-dependent cell growth. May be a tumor suppressor gene candidate involved in myeloid tumors with the deletion of the 20q11 region.Tissue specificity:Ubiquitously expressed in fetal and adult tissues. Highly expressed in adult brain, heart, lung, kidney, lymph node, appendix, thymus, testis, uterus, small intestine, prostate and thymus. |
| Application Dilution | |
| WB | 1:300-5000 |
| ELISA | 1:500-1000 |
| IHC-P | 1:200-400 |
| IHC-F | 1:100-500 |